Authors: Ozdemir, V Kalow, W Posner, P Collins, EJ Kennedy, JL Tang, BK Albers, LJ Reist, C Roy, R Walkes, W Afra, P

Citation: V. Ozdemir et al., CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia, J CL PSYCH, 21(4), 2001, pp. 398-407

Authors: Sy, SKB Tang, BK Pastrakuljic, A Roberts, EA Kalow, W

Citation: Skb. Sy et al., Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine, EUR J CL PH, 57(5), 2001, pp. 377-386

Authors: Ozdemir, V Kalow, W Tang, BK Paterson, AD Walker, SE Endrenyi, L Kashuba, ADM

Citation: V. Ozdemir et al., Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, PHARMACOGEN, 10(5), 2000, pp. 373-388

Authors: Kalow, W Endrenyi, L Tang, BK

Citation: W. Kalow et al., Repeat administration of drugs as a means to assess the genetic component in pharmacological variability, PHARMACOL, 58(6), 1999, pp. 281-284

Authors: Kalow, W Ozdemir, V Tang, BK Tothfalusi, L Endrenyi, L

Citation: W. Kalow et al., The science of pharmacological variability: An essay, CLIN PHARM, 66(5), 1999, pp. 445-447

Authors: Kurata, N Nishimura, Y Iwase, M Fischer, NE Tang, BK Inaba, T Yasuhara, H

Citation: N. Kurata et al., Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1, XENOBIOTICA, 28(11), 1998, pp. 1041-1047